Why the study?
Does early intracoronary administration of nicorandil improve coronary blood flow and clinical outcomes in patients with STEMI undergoing primary PCI?
Does early intracoronary administration of nicorandil improve coronary blood flow and clinical outcomes in patients with STEMI undergoing primary PCI?
Early intracoronary nicorandil during primary PCI in STEMI patients may improve coronary blood flow, reduce reperfusion arrhythmia, and decrease in-hospital cardiovascular mortality and re-hospitalization.
May support adjunctive nicorandil in acute settings; hypothesis-generating and should not change practice without RCTs.
day of admission, the nicorandil group had significantly lower values of brain natriuretic peptide (348.45±112.32 pg/ml vs. 541.11±152.68 pg/ml, p=0.021) and left ventricular end-diastolic diameter (54.12±3.56 mm vs. 60.62±4.98 mm, p=0.011) than the control group. Nicorandil group had a significantly higher number of patients who attained TIMI 3 (p=0.022), TMPG 3 (p=0.034), and STR (p=0.008) than the control group. Ventricular arrhythmia was significantly lower in the nicorandil group than in the control group at 24 hours following pPCI (p=0.012). Conclusion Early intracoronary administration of nicorandil during pPCI may decrease the occurrence of NRP, in-hospital cardiovascular mortality, and re-hospitalization rates, as well as improve coronary blood flow and reduce reperfusion arrhythmia in STEMI patients.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: